PURPOSE: To evaluate the radioprotective effect of lidocaine, amifostine and pilocarpine on lacrimal glands. METHODS: Twenty-five rabbits were randomized into five groups: the control, irradiated/sham-treated, irradiated/lidocaine-pretreated, irradiated/amifostine-pretreated and irradiated/pilocarpine-pretreated groups. One week before irradiation, 72 h and 1 month afterward, the inferior lacrimal gland was investigated histomorphologically, immunohistochemically [tenascin-C and alpha smooth muscle actin (alpha-SMA)] and functionally using scintigraphy and the Schirmer test. RESULTS: Compared with control animals, the lacrimal ejection fraction (LEF) in the irradiated/sham-treated group was significantly reduced 72 h afterwards. Pilocarpine- as well as amifostine-pretreated animals showed a slightly lower reduction. Lidocaine stabilized the LEF. Immunohistochemically, a significant loss of alpha-SMA and an up-regulation of tenascin-C expression in irradiated/untreated glands were evident. Pretreatment with lidocaine and amifostine-but not with pilocarpine-induced lower up-regulation of TN-C expression 72 h after radiation. One month after irradiation a reduction of the immunhistochemical changes at all was found. Ultrastructural damage was observed in irradiated/non-treated and pilocarpine-pretreated glands, whereas lidocaine and amifostine preserved the ultrastructure. CONCLUSION: Morphologic and functional findings could prove a prevailing protection profile of amifostine and especially of lidocaine on lacrimal glands. This may provide a prophylactic approach in the radioprotection of the lacrimal glands during radiotherapy of the orbital region.
PURPOSE: To evaluate the radioprotective effect of lidocaine, amifostine and pilocarpine on lacrimal glands. METHODS: Twenty-five rabbits were randomized into five groups: the control, irradiated/sham-treated, irradiated/lidocaine-pretreated, irradiated/amifostine-pretreated and irradiated/pilocarpine-pretreated groups. One week before irradiation, 72 h and 1 month afterward, the inferior lacrimal gland was investigated histomorphologically, immunohistochemically [tenascin-C and alpha smooth muscle actin (alpha-SMA)] and functionally using scintigraphy and the Schirmer test. RESULTS: Compared with control animals, the lacrimal ejection fraction (LEF) in the irradiated/sham-treated group was significantly reduced 72 h afterwards. Pilocarpine- as well as amifostine-pretreated animals showed a slightly lower reduction. Lidocaine stabilized the LEF. Immunohistochemically, a significant loss of alpha-SMA and an up-regulation of tenascin-C expression in irradiated/untreated glands were evident. Pretreatment with lidocaine and amifostine-but not with pilocarpine-induced lower up-regulation of TN-C expression 72 h after radiation. One month after irradiation a reduction of the immunhistochemical changes at all was found. Ultrastructural damage was observed in irradiated/non-treated and pilocarpine-pretreated glands, whereas lidocaine and amifostine preserved the ultrastructure. CONCLUSION: Morphologic and functional findings could prove a prevailing protection profile of amifostine and especially of lidocaine on lacrimal glands. This may provide a prophylactic approach in the radioprotection of the lacrimal glands during radiotherapy of the orbital region.
Authors: J G Letschert; D González González; J Oskam; L Koornneef; J D van Dijk; R Boukes; J Bras; P van Heerde; H Bartelink Journal: Radiother Oncol Date: 1991-09 Impact factor: 6.280
Authors: J M Roesink; A W Konings; C H Terhaard; J J Battermann; H H Kampinga; R P Coppes Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: F B Vivino; I Al-Hashimi; Z Khan; F G LeVeque; P L Salisbury; T K Tran-Johnson; C C Muscoplat; M Trivedi; B Goldlust; S C Gallagher Journal: Arch Intern Med Date: 1999-01-25
Authors: Marjan Farid; Anshu Agrawal; Daniel Fremgen; Jeremiah Tao; He Chuyi; Anthony B Nesburn; Lbachir BenMohamed Journal: Ocul Immunol Inflamm Date: 2014-12-23 Impact factor: 3.070
Authors: Kimberly F Whelan; Kayla Stratton; Toana Kawashima; John W Waterbor; Robert P Castleberry; Marilyn Stovall; Charles A Sklar; Roger J Packer; Pauline Mitby; Candice L Aitken; Julie Blatt; Leslie L Robison; Ann C Mertens Journal: Pediatr Blood Cancer Date: 2010-01 Impact factor: 3.167